Combating Substance Abuse in Sports with LC/MS/MS Systems
News Apr 20, 2006
HFL has announced that it is using Applied Biosystems LC/MS/MS Systems, including a 4000 Q TRAP® and API 2000®, API 3000™, API 4000™ and API 5000™ Systems for sports doping control and pharmaceutical contract research.
"HFL's pharmaceutical contract research business has grown significantly over the last few years and, since our WADA accreditation in 2004, we have been doing all the routine screening for banned substances in athletes as well as racing animals," explained Dr Steve Pleasance, Director of Contract Research at HFL. "Samples are routinely sent to us from national and international sports events."
"Traditionally, drug surveillance used GC/MS methods, but we have introduced LC/MS techniques to combat the recent changes in abused substances, which have become more potent and more polar."
"The Applied Biosystems' LC/MS/MS Systems are essentially the industry standard; we primarily acquired them for quantitative analyses for our pharmaceutical contract research, but we have naturally progressed into using them for drug surveillance as we can perform qualitative LC/MS assays that detect 50 or more analytes simultaneously."
"We need to perform a variety of different types of analyses; for human athletics surveillance there is a list of prohibited substances that we routinely test for."
"However, when looking at horse racing samples, for example, we need to be able to identify, as well as screen for, a whole host of different compounds - it really is a case of looking for a needle in a haystack!"
Missing Link Between Blow Flies and Possible Pathogen TransmissionNews
Determining whether blow flies have consumed animal fecal material versus animal tissue has important implications for both human public health and animal conservation. A recent study shows how that determination can be made.READ MORE
A Breath Test for Early Diagnosis of Oesophageal and Gastric CancerNews
In a multi-centre clinical trial of 335 patients, a new breath test can identify oesophageal and gastric cancer from benign diseases with 85 per cent accuracy. Unlike other methods, the test is non-invasive.READ MORE